. .. . .. . .

. . .

. . .

.1. , . 2

2. DNA, , . 1

3. DNA, DNA 3

Devlin T . 2, 4 ,7

Lehninger T . 8, 9

. 24, 25.

.

4. RNA

2

5. - 2

6. 3

7.

4

.

Devlin T . 2, 4, 5, 6, 7, 8.

. 25.

Lehninger T . 8, 9, 12.8 , 12.10

. 24, 25, 26, 27, 28.

.

1. O (2 )

Devlin (23.1, 23.2)

Lehninger (23.1)2. -- (1 )

Devlin (. 23.3: . 1347-1351, . 23.4: . 1359-1365, . 23.6: . 1374-1378)

Loffler (.346-348, 375-376)

3. ( ) (1 )

Devlin (. 1351-1353)

Loffler (.352-360, 371-374)

4. (--) (1 )

Devlin ( 23.7, 23.8)

5. (1 )

6. (1 )

Lehninger (23.4) 7. (1 )

.

6

Lehninger 1149-1186

- 2

Devlin 23

1

Devlin (. 1393-1396)

. . 5

( DNA / / .

( ).

( , ).

.

.

Devlin 13 & 25

Lehninger 12 & 28

. 2

1. EGFR

2. HER-2

1) Devlin 13 & 252) Lehninger 12 & 283) M.V. Karamouzis & A.G. Papavassiliou: The IGF-1 network in lung carcinoma therapeutics, Trends Mol Med, 12:595-602, 2006.

4) M.V. Karamouzis, J.R. Grandis & A. Argiris: Therapies against epidermal growth factor receptor in aerodigestive carcinomas. JAMA, 298: 70-82, 2007.

5) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Trastuzumab Mechanism of action and use in clinical practice, New Engl J Med, 357: 1664, 2007.

6) M.V. Karamouzis, A. Argiris, D. Raben & R. Ferris: Head and Neck Cancer, Lancet, 371: 1695-1709, 2008.

7) M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou: Targeting c-Met as a strategy to overcome cross-talk related resistance to EGFR protein -targeting agents in cancer therapeutics, Lancet Oncol, 10: 709-77, 2009.